Detecting Cancer Metabolites in Blood Samples
Author Information
Author(s): J.B. Brooks, P.L. Almenoff, M.I. Daneshvar, A.H. Johnson, V.J. Spechart, M.T. Basta, S.E. Unger, J.N. King, B. Schwartz
Primary Institution: Centers for Disease Control
Hypothesis
Can frequency-pulsed electron-capture gas-liquid chromatography (FPEC-GLC) effectively detect malignancy-associated metabolites in cancer patients' sera?
Conclusion
The study suggests that FPEC-GLC can reliably detect specific metabolites associated with malignancy, indicating its potential for cancer diagnosis and monitoring treatment response.
Supporting Evidence
- FPEC-GLC detected two peaks in cancer patients that were absent in healthy controls.
- The presence of these peaks was associated with malignancy and treatment response.
- Sensitivity of the test was 82% for detecting malignancy.
Takeaway
Scientists found two special markers in the blood of cancer patients that can help doctors know if someone has cancer and how well treatment is working.
Methodology
Serum samples from 52 cancer patients and 94 controls were analyzed using FPEC-GLC to identify specific metabolites.
Potential Biases
Potential bias in patient selection and classification of treatment effectiveness.
Limitations
The study did not have uniform objective criteria for classifying treatment effectiveness and lacked longitudinal data for individual patients.
Participant Demographics
Patients ranged in age from 2 to 75 years, with a mean age of 55; included various cancer types and treatment statuses.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website